Browsing by Author Sever, Peter

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2017Clinical efficacy and safety of evolocumab in high-risk patients receiving a statin: Secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trialKeech, Anthony (Tony); Ferreira, Jorge; Giugliano, Robert P; Huber, Kurt; Lewis, Basil S.; Murphy, S; Pedersen, T; Pineda, Armando Lira; Sabatine, Marc S.; Sever, Peter; Somaratne, Ransi; Tokgozoglu, S. Lale; NH&MRC Clinical Trials CentreClinical efficacy and safety of evolocumab in high-risk patients receiving a statin: Secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a randomized clinical trial, JAMA Cardiology, vol.2, 12, 2017,pp 1385-1391
2017Cognitive function in a randomized trial of evolocumabKeech, Anthony (Tony); Giugliano, Robert P; Honarpour, Narimon; Im, Kyungah; Kanevsky, Estella; Kurtz, C; Mach, Francois; Ott, Brian R.; Pedersen, Terje R; Robinson, Jennifer; Sabatine, Marc S.; Schneider, J; Sever, Peter; Wang, Huei; Wasserman, Scott M; Zavitz, Kenton H.; NH&MRC Clinical Trials CentreCognitive function in a randomized trial of evolocumab, New England Journal of Medicine, vol.377, 7, 2017,pp 633-643
2017Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular diseaseKeech, Anthony (Tony); Fonarow, Gregg; Giugliano, Robert P; Lindgren, Peter; Pedersen, Terje R; Qian, Yi; Sabatine, Marc S.; Sever, Peter; Somaratne, Ransi; van Hout, Ben; Villa, Guillermo; NH&MRC Clinical Trials CentreCost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease, JAMA Cardiology, vol.2, 10, 2017,pp 1069-1078
2017Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trialKeech, Anthony (Tony); Giugliano, Robert P; Honarpour, Narimon; Kurtz, C; Mach, Francois; Ott, Brian R.; Pedersen, T; Sabatine, Marc S.; Schneider, J; Sever, Peter; Wang, Huei; Wasserman, Scott M; Zavitz, Kenton H.; NH&MRC Clinical Trials CentreDesign and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial, Clinical Cardiology, vol.40, 2, 2017,pp 59-65
2016Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trialKeech, Anthony (Tony); Giugliano, Robert P; Honarpour, Narimon; Liu, Thomas; Pedersen, Terje R; Sabatine, Marc S.; Scott, Rob; Sever, Peter; Wang, Huei; Wasserman, Scott M; NH&MRC Clinical Trials CentreRationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial, American Heart Journal, vol.173, N/A, 2016,pp 94-101